1 week Ago
NEW YORK , Nov. 12, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW ) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Edwards investors who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024 .
Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=111413&wire=4 EW investors may also contact Joseph E. Levi, Esq.
via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Edwards' expected revenue for the fiscal year 2024, particularly as it related to the growth of the Company's core product, Transcatheter Aortic Valve Replacement ("TAVR"). Defendants' statements included, among other things, strong commitment to the TAVR platform, confidence in the Company's ability to capitalize on a subset of untreated patients through scaling of its various patient activation activities, and continued claims of significant demand in allegedly lower-penetrated markets.
On July 24, 2024 , Edwards unveiled below-expectation financial results for the second quarter of fiscal 2024 and, in particular, slashed its revenue guidance for the TAVR platform for the full fiscal year 2024. The Company attributed the TAVR setback on the "continued growth and expansion of structural heart therapies ..
. [which] put pressure on hospital workflows." Investors understood this to mean that developments in new procedures, including defendant's own Transcatheter Mitral and Tricuspid Therapies ("TMTT"), put significant strain on hospital structural heart teams such that they were underutilizing TAVR, despite the Company's continued claim of a significantly undertreated patient population.
Moreover, the Company announced three acquisitions during the second quarter designed to embolden their treatments alternative to TAVR, suggesting further that the company was aware of the potential for the TAVR platform's decelerated growth. Investors and analysts reacted immediately to Edwards' revelations. The price of Edwards' common stock declined dramatically.
From a closing market price of $86.95 per share on July 24, 2024 , Edwards' stock price fell to $59.70 per share on July 25, 2024 , a decline of about 31.
34% in the span of just a single day. WHAT'S NEXT? If you suffered a loss in Edwards during the relevant time frame, you have until December 13, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases.
Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States . CONTACT: Levi & Korsinsky, LLP Joseph E.
Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 www.
zlk.com SOURCE Levi & Korsinsky, LLP.
